Finkelstein Thompson LLP, a member of the Plaintiffs Steering Committee, is prosecuting actions against GlaxoSmithKline PLC's marketing and promotion of the prescribed medications Avandia (rosiglitazone maleate), Avandamet (a combination of rosiglitazone maleate and metformin) and Avandaryl (a combination of rosiglitazone maleate and glimepiride) (collectively, "Avandia").  Avandia is used to treat Type II diabetes mellitus.  Avandia was approved by the U.S. Food and Drug Administration ("FDA") on May 25, 1999, Avandamet was approved on October 10, 2002 and Avandaryl was approved on November 23, 2005.  Recent studies have illustrated that the widely-prescribed Avandia increases the risk of a heart attack or heart-related disease by 43 percent.  Additionally, on June 6, 2007, the FDA ordered GlaxoSmithKline to add a "black box" warning to Avandia, strengthening existing warnings regarding the use of Avandia and an increased risk of developing heart-related problems.  GlaxoSmithKline concealed and misrepresented the significant heart attack or heart-related disease risks associated with the use of Avandia.  Many Avandia users now face the dangerous increased risk of experiencing a heart attack and/or developing a heart-related disease. Plaintiffs in this action seek legal remedies in connection with personal injury, medical monitoring, and refunds of their out-of-pocket costs.

If you purchased the prescription drugs Avandia (rosiglitazone maleate), Avandamet (a combination of rosiglitazone maleate and metformin) and Avandaryl (a combination of rosiglitazone maleate and glimepiride) on or after May 25, 1999 and wish to discuss your rights and interests in this matter or have relevant information, please either submit a form, email us, or contact our Washington, DC office toll-free at (877) 337-1050.